Celgene Medical Director US Medical Affairs Multiple Myeloma in Summit, New Jersey
Celgene is a global biopharmaceutical company leading the way in medical innovation to help patients live longer, better lives. Our purpose as a company is to discover and develop therapies that will change the course of human health. We value our passion for patients, quest for innovation, spirit of independence and love of challenge. With a presence in more than 70 countries, and growing - we look for talented people to grow our business, advance our science and contribute to our unique culture.
The Medical Director, Multiple Myeloma, US Medical Affairs will report to the Executive Director, Multiple Myeloma, USMA. He/she will be headquarters based and will provide scientific/medical leadership and support for compounds in various stages of clinical development, as well as approved products in that therapeutic area. This individual will support the design and implementation of an integrated medical plan within the US, under the direction of Executive Director and in coordination with the Global Development Team. They will take responsibility for the evaluation and support of investigator-initiated trials and registry studies and lead any potential Celgene-sponsored medical affairs trials. He/she will represent US Medical Affairs as needed, serving as a therapeutic area expert in strategic and tactical discussions and presentations with internal colleagues, including the Global Development Team, as well as external experts and investigators.
Responsibilities will include, but are not limited to, the following:
Strategic and Tactical Planning: Responsibility for the Medical Affairs aspects of the following plans, in alignment with global plans, and their timely updates:
Launch plans for new products or new indication launches
Strategic and tactical plan
Represent US Medical Affairs as a therapeutic area expert in both internal and external venues including the Global Development Team, clinical sub-teams, and advisory boards / steering committees. Serve as medical monitor for Medical Affairs sponsored trials including registries, intervention and non-intervention trials. Lead/support various Medical Affairs cross-functional working groups. Represent Celgene at professional meetings, congresses, and local symposia. Collaborate with Medical Affairs colleagues to define, guide and execute therapeutic regional strategies and tactics with appropriate use of resources. Provide high quality clinical input and review of: Disease strategy plans, abstracts, posters, slides, manuscripts, educational materials, IIT protocols, steering committee and advisory board meeting objectives, Medical information letters, Commercial Brand plans, Scientific educational grant requests and patient advocacy grant requests Track priority Medical Affairs tactics and performance to goals/budget Perform research and analytics and provide recommendations to support quality medical decisions regarding clinical research, consultancy, and internal planning. Partner with Scientific Communications on developing timely publication strategy and plan, gap analysis, and key messages. Assist with data summaries, preparation for site visits/corporate visits/payor presentations. Interaction with key stakeholders, as a therapeutic area medical strategy expert:
Medical Affairs partners in therapeutic area
Global Medical Affairs Leadership
Global steering committees
Scientific Advisory Boards
The ideal candidate will have the following mix of professional and personal characteristics:
MD or DO, preferably board certified in Hematology/Oncology.
A minimum of 7-10 years academic/industry experience strongly preferred.
Expertise in the conduct of clinical trials in hematology/oncology.
Excellent analytical skills and solid experience in translating medical/clinical information into medical affairs strategies.
Proficiency in critical data review and interpretation.
Matrix leadership of cross-functional teams.
Excellent oral and written communication skills, including presentations to large groups, facilitation of interactive discussions, and 1:1 discussions with thought leaders.
Demonstrated customer focus orientation & credibility with customers.
Knowledge/application of data sources, reports and tools for the creation of solid plans.
Regular travel will be required (approx 20-25%).
Celgene is committed to equal opportunity in the terms and conditions of employment for all employees and job applicants without regard to race, color, religion, sex, sexual orientation, age, gender identity or gender expression, national origin, disability or veteran status. Celgene complies with all applicable national, state and local laws governing nondiscrimination in employment as well as employment eligibility verification requirements of the Immigration and Nationality Act. All applicants must have authorization to work for Celgene in the U.S.COMMITTED TO IMPROVING THE LIVES OF PATIENTS WORLDWIDE
At Celgene, we seek to deliver truly innovative and life-changing drugs for our patients. Our vision as a company is to build a major global biopharmaceutical corporation while focusing on the discovery, the development, and the commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions.
“At Celgene, we seek to deliver truly innovative and life-changing drugs for our patients.”
There are more than 300 clinical trials at major medical centers using compounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma, myelodysplastic syndromes, chronic lymphocytic leukemia (CLL), non-Hodgkin’s lymphoma (NHL), triple-negative breast cancer and pancreatic cancer. As committed as we are to clinical accomplishment, we are equally committed to patient support, which is a guiding principle at Celgene. We believe all who can benefit from our discoveries should have the opportunity to do so. Celgene puts patients first with industry-leading programs that provide information, support and access to our innovative therapies.